Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability